Literature DB >> 32393978

Challenges in the diagnosis and discovery of rare genetic disorders using contemporary sequencing technologies.

Eleanor G Seaby, Sarah Ennis.   

Abstract

Next generation sequencing (NGS) has revolutionised rare disease diagnostics. Concomitant with advancing technologies has been a rise in the number of new gene disorders discovered and diagnoses made for patients and their families. However, despite the trend towards whole exome and whole genome sequencing, diagnostic rates remain suboptimal. On average, only ~30% of patients receive a molecular diagnosis. National sequencing projects launched in the last 5 years are integrating clinical diagnostic testing with research avenues to widen the spectrum of known genetic disorders. Consequently, efforts to diagnose genetic disorders in a clinical setting are now often shared with efforts to prioritise candidate variants for the detection of new disease genes. Herein we discuss some of the biggest obstacles precluding molecular diagnosis and discovery of new gene disorders. We consider bioinformatic and analytical challenges faced when interpreting next generation sequencing data and showcase some of the newest tools available to mitigate these issues. We consider how incomplete penetrance, non-coding variation and structural variants are likely to impact diagnostic rates, and we further discuss methods for uplifting novel gene discovery by adopting a gene-to-patient-based approach.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  diagnostic odyssey; diagnostics; exome sequencing; genomics; novel gene discovery; rare disease

Mesh:

Year:  2020        PMID: 32393978     DOI: 10.1093/bfgp/elaa009

Source DB:  PubMed          Journal:  Brief Funct Genomics        ISSN: 2041-2649            Impact factor:   4.241


  4 in total

1.  Classification of non-coding variants with high pathogenic impact.

Authors:  Lambert Moyon; Camille Berthelot; Alexandra Louis; Nga Thi Thuy Nguyen; Hugues Roest Crollius
Journal:  PLoS Genet       Date:  2022-04-29       Impact factor: 5.917

2.  Diagnostic testing laboratories are valuable partners for disease gene discovery: 5-year experience with GeneMatcher.

Authors:  Meghan C Towne; Mari Rossi; Bess Wayburn; Jennifer M Huang; Kelly Radtke; Wendy Alcaraz; Kelly D Farwell Hagman; Deepali N Shinde
Journal:  Hum Mutat       Date:  2022-03-02       Impact factor: 4.700

3.  Mendelian gene identification through mouse embryo viability screening.

Authors:  Pilar Cacheiro; Carl Henrik Westerberg; Jesse Mager; Mary E Dickinson; Lauryl M J Nutter; Violeta Muñoz-Fuentes; Chih-Wei Hsu; Ignatia B Van den Veyver; Ann M Flenniken; Colin McKerlie; Stephen A Murray; Lydia Teboul; Jason D Heaney; K C Kent Lloyd; Louise Lanoue; Robert E Braun; Jacqueline K White; Amie K Creighton; Valerie Laurin; Ruolin Guo; Dawei Qu; Sara Wells; James Cleak; Rosie Bunton-Stasyshyn; Michelle Stewart; Jackie Harrisson; Jeremy Mason; Hamed Haseli Mashhadi; Helen Parkinson; Ann-Marie Mallon; Damian Smedley
Journal:  Genome Med       Date:  2022-10-13       Impact factor: 15.266

Review 4.  Strategies to Uplift Novel Mendelian Gene Discovery for Improved Clinical Outcomes.

Authors:  Eleanor G Seaby; Heidi L Rehm; Anne O'Donnell-Luria
Journal:  Front Genet       Date:  2021-06-17       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.